Assessing the Effectiveness of Add-On Therapy of Palmitoylethanolamide to Standard Therapy in Diabetic Peripheral Neuropathy
Background: Diabetic Peripheral Neuropathy (DPN) is a common yet challenging complication of diabetes, particularly in managing neuropathic pain. Palmitoylethanolamide (PEA), a naturally occurring nutraceutical from the ALIAmides group, has demonstrated potential for pain modulation, inflammation r...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center for Rational Use of Drugs (RCRUD)
2024-12-01
|
| Series: | Journal of Pharmaceutical Care |
| Subjects: | |
| Online Access: | https://jpc.tums.ac.ir/index.php/jpc/article/view/763 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558582490824704 |
|---|---|
| author | Velusamy Sivakumar Thangavelu Saravanan V.K. Damini |
| author_facet | Velusamy Sivakumar Thangavelu Saravanan V.K. Damini |
| author_sort | Velusamy Sivakumar |
| collection | DOAJ |
| description |
Background: Diabetic Peripheral Neuropathy (DPN) is a common yet challenging complication of diabetes, particularly in managing neuropathic pain. Palmitoylethanolamide (PEA), a naturally occurring nutraceutical from the ALIAmides group, has demonstrated potential for pain modulation, inflammation reduction, and improving quality of life.
Method: A 9-month prospective observational study at PSG Hospital evaluated the impact of adding oral capsule PEA (708 mg in two divided doses) to standard therapy for DPN patients unresponsive to maximum tolerated dosages of Gabapentin, Pregabalin, amitriptyline, or duloxetine. The outcomes were the pain severity and quality of life. Pain was assessed using the Visual Analog Scale (VAS), sensitivity was evaluated via monofilament testing, and quality of life was measured using the American Chronic Pain Association (ACPA) Quality of Life Scale (QOLS).
Results: Sixty patients with DPN were treated with adjunctive PEA and monitored for 8 weeks. Pain scores decreased significantly (6.05±1.096 to 4.15±1.233 at 4 weeks and 3.57±1.155 at 8 weeks, p˂0.05). Sensitivity improved via monofilament testing (7.12±1.58 to 9.43±0.78). Quality of life scores rose from 7.67 to 9.41 at 4 weeks and 9.68 at 8 weeks, indicating notable benefits.
Conclusion: PEA proved effective as a supplemental treatment for nonresponsive DPN patients, yielding significant reductions in pain, enhanced sensitivity, and better quality of life. Importantly, no side effects were reported, affirming its tolerability and safety.
|
| format | Article |
| id | doaj-art-34e9f3f84f774e5288123c4028e95be7 |
| institution | Kabale University |
| issn | 2322-4630 2322-4509 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Research Center for Rational Use of Drugs (RCRUD) |
| record_format | Article |
| series | Journal of Pharmaceutical Care |
| spelling | doaj-art-34e9f3f84f774e5288123c4028e95be72025-01-06T08:43:47ZengResearch Center for Rational Use of Drugs (RCRUD)Journal of Pharmaceutical Care2322-46302322-45092024-12-0112410.18502/jpc.v12i4.17454Assessing the Effectiveness of Add-On Therapy of Palmitoylethanolamide to Standard Therapy in Diabetic Peripheral NeuropathyVelusamy Sivakumar0Thangavelu Saravanan1V.K. Damini2Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.Department of General Medicine, PSG Hospitals, Coimbatore, Tamil Nadu, India.Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India. Background: Diabetic Peripheral Neuropathy (DPN) is a common yet challenging complication of diabetes, particularly in managing neuropathic pain. Palmitoylethanolamide (PEA), a naturally occurring nutraceutical from the ALIAmides group, has demonstrated potential for pain modulation, inflammation reduction, and improving quality of life. Method: A 9-month prospective observational study at PSG Hospital evaluated the impact of adding oral capsule PEA (708 mg in two divided doses) to standard therapy for DPN patients unresponsive to maximum tolerated dosages of Gabapentin, Pregabalin, amitriptyline, or duloxetine. The outcomes were the pain severity and quality of life. Pain was assessed using the Visual Analog Scale (VAS), sensitivity was evaluated via monofilament testing, and quality of life was measured using the American Chronic Pain Association (ACPA) Quality of Life Scale (QOLS). Results: Sixty patients with DPN were treated with adjunctive PEA and monitored for 8 weeks. Pain scores decreased significantly (6.05±1.096 to 4.15±1.233 at 4 weeks and 3.57±1.155 at 8 weeks, p˂0.05). Sensitivity improved via monofilament testing (7.12±1.58 to 9.43±0.78). Quality of life scores rose from 7.67 to 9.41 at 4 weeks and 9.68 at 8 weeks, indicating notable benefits. Conclusion: PEA proved effective as a supplemental treatment for nonresponsive DPN patients, yielding significant reductions in pain, enhanced sensitivity, and better quality of life. Importantly, no side effects were reported, affirming its tolerability and safety. https://jpc.tums.ac.ir/index.php/jpc/article/view/763PalmitoylethanolamidePeripheral neuropathyConventional therapyneuroprotective effectPain. |
| spellingShingle | Velusamy Sivakumar Thangavelu Saravanan V.K. Damini Assessing the Effectiveness of Add-On Therapy of Palmitoylethanolamide to Standard Therapy in Diabetic Peripheral Neuropathy Journal of Pharmaceutical Care Palmitoylethanolamide Peripheral neuropathy Conventional therapy neuroprotective effect Pain. |
| title | Assessing the Effectiveness of Add-On Therapy of Palmitoylethanolamide to Standard Therapy in Diabetic Peripheral Neuropathy |
| title_full | Assessing the Effectiveness of Add-On Therapy of Palmitoylethanolamide to Standard Therapy in Diabetic Peripheral Neuropathy |
| title_fullStr | Assessing the Effectiveness of Add-On Therapy of Palmitoylethanolamide to Standard Therapy in Diabetic Peripheral Neuropathy |
| title_full_unstemmed | Assessing the Effectiveness of Add-On Therapy of Palmitoylethanolamide to Standard Therapy in Diabetic Peripheral Neuropathy |
| title_short | Assessing the Effectiveness of Add-On Therapy of Palmitoylethanolamide to Standard Therapy in Diabetic Peripheral Neuropathy |
| title_sort | assessing the effectiveness of add on therapy of palmitoylethanolamide to standard therapy in diabetic peripheral neuropathy |
| topic | Palmitoylethanolamide Peripheral neuropathy Conventional therapy neuroprotective effect Pain. |
| url | https://jpc.tums.ac.ir/index.php/jpc/article/view/763 |
| work_keys_str_mv | AT velusamysivakumar assessingtheeffectivenessofaddontherapyofpalmitoylethanolamidetostandardtherapyindiabeticperipheralneuropathy AT thangavelusaravanan assessingtheeffectivenessofaddontherapyofpalmitoylethanolamidetostandardtherapyindiabeticperipheralneuropathy AT vkdamini assessingtheeffectivenessofaddontherapyofpalmitoylethanolamidetostandardtherapyindiabeticperipheralneuropathy |